← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $287B	875	+27	+3%	$22.2B
2	2 Charles River Laboratories CRL $14.7B	255	-7	-3%	$2.79B
3	3 DELISTED SANGAMO THERAPEUTICS INC SGMO	157	+1	+0.6%	$527M
4	4 DELISTED bluebird bio BLUE	123	+19	+18%	$846M
5	5 Sarepta Therapeutics SRPT $1.87B	123	-5	-4%	$548M
6	6 Precigen PGEN $2.64B	102	-5	-5%	$1.64B
7	7 Ultragenyx Pharmaceutical RARE $1.49B	100	+19	+23%	$1.5B
8	8 PTC Therapeutics PTCT $5.11B	99	+15	+18%	$1.07B
9	ISEE 9 DELISTED IVERIC bio, Inc. Common Stock ISEE	92	-6	-6%	$1.13B
10	10 DELISTED CATALENT, INC. CTLT	80	+80	–	$3.14B
11	11 DELISTED Adverum Biotechnologies ADVM	58	+58	–	$420M
12	12 Lineage Cell Therapeutics LCTX $244M	57	-5	-8%	$70.1M
13	ATHX 13 DELISTED Athersys, Inc. Common Stock ATHX	48	+2	+4%	$11.2M
14	AGTC 14 DELISTED Applied Genetic Technologies Corporation AGTC	42	+4	+11%	$104M
15	15 DELISTED Carisma Therapeutics CARM	42	+3	+8%	$130M
16	16 Fortress Biotech FBIO $64.7M	39	-9	-19%	$16.3M
17	17 Imunon IMNN $5.84M	34	-2	-6%	$8.44M
18	18 Opus Genetics IRD $333M	31	-4	-11%	$5.71M
19	19 Vericel Corp VCEL $2.12B	31	+5	+19%	$26M
20	20 Pluri PLUR $12M	27	-1	-4%	$3.07M
21	21 uniQure QURE $1.51B	26	-1	-4%	$31.9M
22	22 Fate Therapeutics FATE $232M	22	0	0%	$52.6M
23	23 Neurogene NGNE $485M	22	+3	+16%	$27.6M
24	24 DELISTED BioLife Solutions BLFS	15	+1	+7%	$1.22M
25	PTE 25 DELISTED PolarityTE, Inc. Common Stock PTE	13	-3	-19%	$311K